hepatitis C

Showing 15 posts of 65 posts found.


European Commission approves first drug for hepatitis D

August 6, 2020
Business Services EC, hepatitis C, hepatitis D

The European Commission has approved Heplcudex (bulvirtide) as the first hepatitis D drug. It was jointly developed by researchers at …


AbbVie’s Mavyret scores FDA label expansion to shorten treatment duration for hepatitis C patients

September 27, 2019
Medical Communications, Sales and Marketing AbbVie, FDA, hepatitis, hepatitis C, mavyret, pharma

The FDA has chosen to expand the existing label for AbbVie’s Mavyret (glecaprevir/pibrentasvir), it has been revealed, to include the …


FDA warns three Hepatitis C drugs may worsen liver function in some rare cases

August 29, 2019
Medical Communications, Research and Development AbbVie, FDA, Gilead, HCV, MSD, hepatitis C, public health

The FDA has warned that three Hepatitis C (HCV) drugs made by AbbVie, Gilead and MSD are worsening liver function …

FDA approves AbbVie’s Mavyret for children with Hepatitis C (HCV)

May 1, 2019
Research and Development AbbVie, HCV, hepatitis C, mavyret, pharma

The FDA has approved AbbVie’s Mavyret tables (glecaprevir/pibrentasvir) as a treatment for hepatitis C (HCV) in children aged 12 to 17 …


Reformulated OxyContin led to spike in Hepatitis C infections

February 5, 2019
Manufacturing and Production OxyContin, USA, hepatitis C, heroin, infectious diseases, opioids

Efforts to create an “abuse deterrent” OxyContin pill inadvertently led to an increase in the number of Hepatitis C infections, …


AbbVie’s case against the NHS thrown out of court

January 22, 2019
Manufacturing and Production AbbVie, HCV, NHS, health, hepatitis C, public health

A judge has thrown US multinational AbbVie’s case against NHS England’s hepatitis C procurement process, out of court. Mr Justice …


Gilead to release generic versions of hep C meds over a decade before patent expiry

September 28, 2018
Medical Communications, Sales and Marketing Epclusa, Gilead, generics, harvoni, hepatitis C, pharma

Gilead has announced its intention to undercut itself by releasing generic versions of its blockbuster drugs for the treatment of …


US court upholds verdict voiding MSD’s claim to $200m from Gilead in patent dispute

April 26, 2018
Sales and Marketing Gilead, MSD, Merck, harvoni, hepatitis C, pharma, sovaldi

MSD has taken a legal hit after a US appeals court upheld a ruling that the pharma giant had illicitly …


New hepatitis C combo boasts 97% cure rate for just $300

April 12, 2018
Research and Development AbbVie, DNDi, Drugs for Neglected Diseases initiative, Gilead, HCV, Pharco Pharmaceuticals, hepatitis C, pharma, sovaldi

A partnership of the not-for-profit organisation Drugs for Neglected Diseases initiative (DNDi) and Egyptian drug firm Pharco Pharmaceuticals is working …


Gilead launches hep C drug Sovaldi in China at one-fifth of US price

November 29, 2017
Research and Development, Sales and Marketing China, Gilead, hepatitis C, pharma, sovaldi

Gilead has officially launched its hepatitis C drug Sovaldi (sofosbuvir) in the Chinese market, but with one major caveat: it …


MSD pulls out of hep C space to Gilead’s relief

October 2, 2017
Sales and Marketing MSD, biotech, drugs, hepatitis C, pharma, pharmaceutical

MSD, known as Merck in North America, has announced that it will curtail its attempts to make an impact in …

J&J backs out of $1.1 billion hep C deal, wiping 22.2% from Achillion’s stock

September 12, 2017
Manufacturing and Production, Sales and Marketing J&J, JJ, Johnson & Johnson, achillion, hepatitis C, pharma

Johnson & Johnson has announced that it is to back out of a $1.1 billion deal with Achillion Pharmaceuticals to …


Nine in 10 people unaware they have hepatitis

July 28, 2017
Medical Communications, Research and Development Gilead, biotech, drugs, hepatitis, hepatitis C, pharma, pharmaceutical

The WHO has released a report on the state of hepatitis prevention and treatment to mark World Hepatitis Day, with …


Regulus CEO heads to exit as company struggles with FDA hold

May 5, 2017
Medical Communications, Research and Development Regulus, hepatitis C

Regulus seemed to be in a good place just last year as its lead drug candidate performed well in a …

Latest content